Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CombinatoRx, Incorporated
CombinatoRx Concentrates on Core Strengths
December 13th, 2008
CombinatoRx, Incorporated (NASDAQ: CRXX) announced a further restructuring, effective immediately, to focus on the core strength of the company: identifying novel product candidates based on unexpected biological synergies. This restructuring will include a planned further reduction of the Company’s Cambridge workforce by approximately 30 employees, bringing the total workforce reduction to approximately 65%. These measures should allow the company to operate without additional equity financing for at least four more years. “Our technology is uniquely capable of delivering important insights into how multiple drugs interacting with multiple targets affect the complex biology of human...
Source: Law & Health Weekly (2008-12-13)
|
|
Advertisement |
|
|
|
